Are investors shorting Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 27,900 shares, a decline of 59.2% from the March 15th total of 68,300 shares. Based on an average daily trading volume, of 33,000 shares, the short-interest ratio is currently 0.8 days. View Range Cancer Therapeutics ETF's Short Interest .

What does CNCR invest in?

Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $17.74 million assets under management.

What stocks does Range Cancer Therapeutics ETF hold?

CNCR invests in 79 holdings. Some of the stocks in their portfolio include Caribou Biosciences (CRBU) , HUTCHMED (HCM) , Recursion Pharmaceuticals (RXRX) , Revolution Medicines (RVMD) , EQRx (EQRX) , Apollomics (APLM) , VectivBio (VECT) , Exscientia (EXAI) , Immunocore (IMCR) and Exelixis (EXEL) .

What is the management fee for Range Cancer Therapeutics ETF?

Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%.

What other stocks do shareholders of Range Cancer Therapeutics ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU) , Intel (INTC) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) , Gilead Sciences (GILD) , Mastercard (MA) , Abbott Laboratories (ABT) , Alibaba Group (BABA) and Quest Diagnostics (DGX) .

NASDAQ:CNCR

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free CNCR Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $14.36
▼
$14.63
50-Day Range: $27.45
▼
$32.25
52-Week Range: $25.99
▼
$35.82

Volume: 1,766 shs
Average Volume: 6,668 shs
Market Capitalization: $12.92 million

Assets Under Management: $17.74 million
Dividend Yield: 2.02%
Net Expense Ratio: 0.79%

Stock Analysis Dividend Headlines Holdings Ownership Ratings Short Interest Social Media

Get Range Cancer Therapeutics ETF alerts:

About Range Cancer Therapeutics ETF

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

CNCR ETF News Headlines

March 15, 2024 | msn.com

Large-scale study explores genetic link between colorectal cancer and meat intake

March 11, 2024 | markets.businessinsider.com

Microbix Unveils Test Controls for Head and Neck Cancer

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 3, 2024 | nasdaq.com

The Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKB

February 22, 2024 | msn.com

FDA approval of cancer treatment provides new weapon against tumors

February 21, 2024 | msn.com

A watershed moment for cancer therapies has arrived

February 5, 2024 | nz.finance.yahoo.com

ETF S.S.-LONCAR CAN.I.ETF (E18B.BE)

January 24, 2024 | msn.com

Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

January 4, 2024 | markets.businessinsider.com

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

See More Headlines

Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer: Exchange Traded Concepts
Fund Name: Range Cancer Therapeutics ETF
Tax Classification: Regulated Investment Company
Stock Exchange: NASDAQ
Current Symbol: NASDAQ:CNCR
Inception Date: 10/13/2015
Fund Manager: Denise M. Krisko
Web: N/A
Phone: N/A

Fund Focus

Asset Class: Equity
Benchmark: Range Cancer Therapeutics Index
Category: Sector
Focus: Health Care
Development Level: Developed Markets
Region: North America
Number of Holdings: 79

Fund Statistics

Assets Under Management: $17.74 million
Average Daily Volume: $35,888.60
Discount/Premium: -0.05%

Administrator, Advisor and Custodian

Administrator: U.S. Bancorp Fund Services, LLC
Advisor: Exchange Traded Concepts, LLC
Custodian: U.S. Bank, N.A.
Distributor: Quasar Distributors, LLC
Transfer Agent: U.S. Bank, N.A.
Trustee: N/A
Lead Market Maker: Jane Street

Options

Optionable: N/A
Short Interest: 27,900 shs

Miscellaneous

Outstanding Shares: 900,000
Beta: 0.90
Creation Unit: 50,000
Creation Fee: $150.00

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Range Cancer Therapeutics ETF Expenses

Type	CNCR	Health Care ETFs	Equity ETFs	NASDAQ ETFs	All ETFs
Management Fee	0.79%	0.56%	0.54%	0.48%	0.51%
Other Expenses	0.00%	0.40%	0.54%	0.34%	0.58%
Total Expense	0.79%	0.72%	0.70%	0.58%	0.70%
Fee Waiver	0.00%	-0.53%	-0.55%	-0.22%	-0.57%
Net Expense	0.79%	0.60%	0.60%	0.54%	0.58%

Range Cancer Therapeutics ETF (CNCR) Holdings & Exposure

Top 10 CNCR Holdings

CNCR Sector Exposure

CNCR Industry Exposure

Full Holdings Details

Similar ETFs

Institutional Ownership

OLD Mission Capital LLC
Bought 16,319 shares on 2/15/2024
Ownership: 1.813%

View All Institutional Transactions

CNCR ETF - Frequently Asked Questions

Are investors shorting Range Cancer Therapeutics ETF?: Range Cancer Therapeutics ETF saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 27,900 shares, a decline of 59.2% from the March 15th total of 68,300 shares. Based on an average daily trading volume, of 33,000 shares, the short-interest ratio is currently 0.8 days.
View Range Cancer Therapeutics ETF's Short Interest.
What does CNCR invest in?: Range Cancer Therapeutics ETF is a equity fund issued by Exchange Traded Concepts. CNCR focuses on health care investments and follows the Range Cancer Therapeutics Index. The fund's investments total to approximately $17.74 million assets under management.
What stocks does Range Cancer Therapeutics ETF hold?: CNCR invests in 79 holdings. Some of the stocks in their portfolio include Caribou Biosciences (CRBU), HUTCHMED (HCM), Recursion Pharmaceuticals (RXRX), Revolution Medicines (RVMD), EQRx (EQRX), Apollomics (APLM), VectivBio (VECT), Exscientia (EXAI), Immunocore (IMCR) and Exelixis (EXEL).

What is the management fee for Range Cancer Therapeutics ETF?: Range Cancer Therapeutics ETF's management fee is 0.79% and has no other recorded expenses or fee waivers. The net expense ratio for CNCR is 0.79%.
What other stocks do shareholders of Range Cancer Therapeutics ETF own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA), Abbott Laboratories (ABT), Alibaba Group (BABA) and Quest Diagnostics (DGX).

This page (NASDAQ:CNCR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

About Range Cancer Therapeutics ETF

CNCR ETF News Headlines

Fund Details

Fund Focus

Fund Statistics

Administrator, Advisor and Custodian

Options

Miscellaneous

Range Cancer Therapeutics ETF Expenses

Range Cancer Therapeutics ETF (CNCR) Holdings & Exposure

Top 10 CNCR Holdings

CNCR Sector Exposure

CNCR Industry Exposure

Similar ETFs

Institutional Ownership

CNCR ETF - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info